Loading
companiesCompany
UbiVac
UbiVac is developing an off-the-shelf cancer vaccine aimed at proteins made from non-coding regions of the genome, with RNA sequencing to check a patient's tumour expresses the targets, and early data in head and neck cancer.
Overview
UbiVac's vaccine targets proteins derived from non-coding genome regions that tumours express, screened per patient by RNA sequencing; Future of Cancer Care Today describes it as clinical-stage with good data in head and neck cancer, accessible through trial enrolment.
Similar pages
- CompanyInvoke Bio
Shares Personalised neoantigen (mRNA) vaccines and the tag fcct-directory.
- CompanyJaime Leandro Foundation
Shares Personalised neoantigen (mRNA) vaccines and the tag fcct-directory.
- InstitutionCeCurio (MVZ Tübingen oncology)
Shares Personalised neoantigen (mRNA) vaccines and the tag fcct-directory.
- CompanyCeGaT
Shares Personalised neoantigen (mRNA) vaccines and the tag fcct-directory.
- InstitutionHouston Methodist Center for RNA Therapeutics
Shares Personalised neoantigen (mRNA) vaccines and the tag fcct-directory.
- CompanyNykode Therapeutics
Shares Personalised neoantigen (mRNA) vaccines, Head and neck squamous cell carcinoma.
- CompanyTransgene
Shares Personalised neoantigen (mRNA) vaccines, Head and neck squamous cell carcinoma.
- RoadmapImmunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity
Shares Personalised neoantigen (mRNA) vaccines, Head and neck squamous cell carcinoma.